Baxter sees Gambro deal neutral to modestly accretive in adjusted FY14 EPS In a company slides presentation Baxter said it sees the Gambro deal neutral to modestly accretive to 2014 adjusted E.P.S. (including estimated amortization of intangible assets); Accretive in 2014 by 20c to 25c per diluted share on a cash basis.
Baxter resumed with a Neutral from Overweight at Piper Jaffray Piper Jaffray analyst Brooks West downgraded Baxter (BAX) to Neutral after resuming coverage of the name. The company, post the spin of Baxalta (BXLT), "has a number of moving pieces that need to be addressed," West tells investors in a research note. He lowered his price target for shares to $39 from $90.